MDS
MCID: MYL009
MIFTS: 73

Myelodysplastic Syndrome (MDS) malady

Categories: Genetic diseases, Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Myelodysplastic Syndrome

Aliases & Descriptions for Myelodysplastic Syndrome:

Name: Myelodysplastic Syndrome 54 12 66 13 14 38 69
Myelodysplastic Syndromes 38 50 29 52 41 42
Myelodysplastic Syndrome, Somatic 54 24 13
Mds 50 24 66

Characteristics:

HPO:

32
myelodysplastic syndrome:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 54 614286
Disease Ontology 12 DOID:0050908
MeSH 42 D009190
MedGen 40 C3463824
ICD10 33 D46
UMLS 69 C2713368

Summaries for Myelodysplastic Syndrome

MedlinePlus : 41 your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. it contains immature cells, called stem cells. the stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting. if you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. many of them die in the bone marrow. this means that you do not have enough healthy cells, which can lead to infection, anemia, or easy bleeding. myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. if you have symptoms, they may include shortness of breath weakness or feeling tired skin that is paler than usual easy bruising or bleeding pinpoint spots under the skin caused by bleeding fever or frequent infections myelodysplastic syndromes are rare. people at higher risk are over 60, have had chemotherapy or radiation therapy, or have been exposed to certain chemicals. treatment options include transfusions, drug therapy, chemotherapy, and blood or bone marrow stem cell transplants. nih: national cancer institute

MalaCards based summary : Myelodysplastic Syndrome, also known as myelodysplastic syndromes, is related to hemophagocytic lymphohistiocytosis and acute lymphocytic leukemia, and has symptoms including myelodysplasia An important gene associated with Myelodysplastic Syndrome is GATA2 (GATA Binding Protein 2), and among its related pathways/superpathways are NF-kappaB Signaling and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Busulfex and Lynparza have been mentioned in the context of this disorder. Affiliated tissues include Placenta and Umbilical Cord, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Disease Ontology : 12 A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets.

NIH Rare Diseases : 50 myelodysplastic syndromes (mds) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. individuals with mds have abnormally low blood cell levels (low blood counts). signs and symptoms associated with mds include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. in some cases, mds may progress to bone marrow failure or an acute leukemia. the exact cause of mds is unknown. it sometimes runs in families, but no disease-causing gene has been identified. treatment depends on the affected individual's age, general health, and type of mds and may include red cell and/or platelet transfusions and antibiotics. last updated: 3/23/2012

OMIM : 54 Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematologic stem cell disorders characterized by... (614286) more...

UniProtKB/Swiss-Prot : 66 Myelodysplastic syndrome: A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS); chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. MDS is considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML).

Wikipedia : 71 Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow... more...

Related Diseases for Myelodysplastic Syndrome

Diseases related to Myelodysplastic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
id Related Disease Score Top Affiliating Genes
1 hemophagocytic lymphohistiocytosis 29.9 CSF2 FLT3 GATA2 IL3 NPM1 NUP98
2 acute lymphocytic leukemia 29.8 FLT3 IL3 RUNX1 WT1
3 leukemia, acute myeloid 28.8 ACSL6 ASXL1 CSF2 EPO FLT3 GATA2
4 unclassified myelodysplastic syndrome 12.0
5 therapy related acute myeloid leukemia and myelodysplastic syndrome 11.9
6 macrocytic anemia, refractory, due to 5q deletion, somatic 11.8
7 acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent 11.8
8 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 11.8
9 acute myeloid leukemia and myelodysplastic syndromes related to radiation 11.8
10 myelodysplastic syndrome, susceptibility, gata2-related 11.7
11 muscular dystrophy 11.6
12 miller-dieker lissencephaly syndrome 11.5
13 walker-warburg syndrome 11.4
14 myelodysplastic myeloproliferative cancer 11.3
15 refractory anemia with excess blasts 11.3
16 alpha-thalassemia myelodysplasia syndrome, somatic 11.2
17 myeloproliferative neoplasm 11.1
18 sideroblastic anemia 11.1
19 dyskeratosis congenita 11.1
20 littoral cell angioma of the spleen 11.1
21 epidermolysis bullosa simplex with muscular dystrophy 11.0
22 leukemia, acute myelomonocytic, somatic, somatic 11.0
23 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 10.9
24 neutropenia, severe congenital 1, autosomal dominant 10.9
25 menkes disease 10.8
26 epidermolysa bullosa simplex with muscular dystrophy 10.8
27 leukemia 10.8
28 refractory anemia 10.8
29 pulmonary fibrosis and/or bone marrow failure, telomere-related, 3 10.7
30 neutropenia, severe congenital 3, autosomal recessive 10.7
31 pelger-huet anomaly 10.7
32 pulmonary fibrosis and/or bone marrow failure, telomere-related, 4 10.7
33 sea-blue histiocyte disease 10.7
34 familial mosaic monosomy 7 syndrome 10.7
35 myeloid leukemia 10.6
36 regional odontodysplasia 10.4 ASXL1 GATA2 SETBP1 TET2
37 acute respiratory distress syndrome 10.4 FLT3 GATA2 NPM1
38 glycogen storage disease type 0 10.4 FLT3 NPM1 WT1
39 abdominal obesity-metabolic syndrome 10.4 ASXL1 RUNX1 SETBP1
40 agammaglobulinemia 8, autosomal dominant 10.4 FLT3 GATA2 NPM1
41 colorectal adenoma 10.4 ASXL1 FLT3 RUNX1 SETBP1 TET2
42 von hippel anomaly 10.4 ASXL1 EPO IL3 RUNX1 TET2
43 acute zonal occult outer retinopathy 10.4 FLT3 NPM1
44 malignant testicular leydig cell tumor 10.4 FLT3 NPM1 RUNX1
45 nephrolithiasis 10.4 CSF2 NRAS SETBP1 TET2
46 familial hyperaldosteronism 10.4 FLT3 NRAS RUNX1 WT1
47 erythrocytosis, somatic 10.4 EPO FLT3 IL3 TET2
48 basilar artery insufficiency 10.4 ASXL1 EPO IL3 TET2
49 dic in newborn 10.4 CSF2 EPO IL3
50 spinal muscular atrophy-dandy-walker malformation-cataracts syndrome 10.4 SF3B1 TET2

Graphical network of the top 20 diseases related to Myelodysplastic Syndrome:



Diseases related to Myelodysplastic Syndrome

Symptoms & Phenotypes for Myelodysplastic Syndrome

Clinical features from OMIM:

614286

Human phenotypes related to Myelodysplastic Syndrome:

32
id Description HPO Frequency HPO Source Accession
1 myelodysplasia 32 HP:0002863

GenomeRNAi Phenotypes related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.91 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.91 FLT3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.91 FLT3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.91 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.91 FLT3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.91 FLT3 PRDM16 SETBP1 ACSL6 WT1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.91 FLT3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.91 PRDM16
9 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.91 ACSL6
10 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.91 SETBP1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.91 ACSL6
12 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.91 WT1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.91 SETBP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.91 FLT3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.91 SETBP1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.91 PRDM16
17 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.91 SETBP1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.91 PRDM16 SETBP1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.91 SETBP1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.91 SETBP1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.91 WT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.91 WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.91 FLT3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.91 WT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.91 WT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.91 WT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.91 WT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.91 FLT3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.91 SETBP1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.91 SETBP1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.91 ACSL6
32 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.91 SETBP1 ACSL6 WT1
33 Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers GR00195-A-3 9.13 NUP98 RUNX1 SF3B1

MGI Mouse Phenotypes related to Myelodysplastic Syndrome:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 NPM1 NRAS NUP98 PRDM16 RUNX1 SF3B1
2 cellular MP:0005384 10.24 WT1 ASXL1 CSF2 EPO FLT3 GATA2
3 cardiovascular system MP:0005385 10.21 CSF2 EPO GATA2 IRF1 NPM1 NRAS
4 growth/size/body region MP:0005378 10.17 ASXL1 CSF2 FLT3 GATA2 NPM1 NRAS
5 endocrine/exocrine gland MP:0005379 10.16 FLT3 GATA2 IRF1 NRAS PRDM16 RUNX1
6 homeostasis/metabolism MP:0005376 10.15 ASXL1 CSF2 EPO FLT3 GATA2 IRF1
7 immune system MP:0005387 10.13 WT1 ASXL1 CSF2 EPO FLT3 IRF1
8 embryo MP:0005380 10.08 CSF2 EPO GATA2 NPM1 NRAS NUP98
9 mortality/aging MP:0010768 10.03 SETBP1 SF3B1 TET2 WT1 ASXL1 CSF2
10 liver/biliary system MP:0005370 9.91 ASXL1 EPO GATA2 NPM1 NRAS PRDM16
11 neoplasm MP:0002006 9.61 ASXL1 CSF2 FLT3 IRF1 NPM1 NRAS
12 normal MP:0002873 9.23 EPO GATA2 IRF1 NRAS PRDM16 RUNX1

Drugs & Therapeutics for Myelodysplastic Syndrome

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Busulfex 17 46 BUSULFAN Orphan Medical Approved February 1999
2
Lynparza 17 46 OLAPARIB AstraZeneca Approved December 2014
3
Revlimid 17 46 LENALIDOMIDE Celgene Approved June 2013

Drugs for Myelodysplastic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 590)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 320-67-2 9444
2
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
3
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
5
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
6
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
7
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
8
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
9
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
10
Vidarabine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 24356-66-9 32326 21704
11
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
12
Lenograstim Approved Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
13
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
14
Deferasirox Approved, Investigational Phase 4,Phase 3,Phase 2 201530-41-8 5493381
15
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
16
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
17
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 171228-49-2 147912
18
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
19
Radium Ra 223 dichloride Approved, Investigational Phase 4 444811-40-9
20
Succinylcholine Approved Phase 4 306-40-1 5314
21
Vitamin C Approved, Nutraceutical Phase 4,Phase 2,Phase 1 50-81-7 5785 54670067
22 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
29 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
33 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
34 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
35 Epoetin alfa Phase 4,Phase 2,Phase 3,Phase 1 113427-24-0
36 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
38 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Hematinics Phase 4,Phase 2,Phase 3,Phase 1
42 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
43 Hormones Phase 4,Phase 3,Phase 2,Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
48 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Iron Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1
50 beta-Lactamase Inhibitors Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 1789)
id Name Status NCT ID Phase
1 A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome Unknown status NCT02013102 Phase 4
2 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4
3 Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome Completed NCT00488436 Phase 4
4 Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) Completed NCT01201811 Phase 4
5 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4
6 A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome Completed NCT01041846 Phase 4
7 An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome Completed NCT01400633 Phase 4
8 Survey on QUality of Life In myeloDisplasia (SQUID) Completed NCT00967564 Phase 4
9 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4
10 Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load Completed NCT00452660 Phase 4
11 Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4
12 This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. Completed NCT01250951 Phase 4
13 Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Completed NCT00673608 Phase 4
14 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4
15 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
16 Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Completed NCT00195533 Phase 4
17 Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor Completed NCT01362985 Phase 4
18 Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects Completed NCT00867932 Phase 4
19 A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. Recruiting NCT02663752 Phase 4
20 A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS) Recruiting NCT02145026 Phase 4
21 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4
22 A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4
23 Radium-223 Dichloride Long-term Follow-up Program Recruiting NCT02312960 Phase 4
24 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Active, not recruiting NCT01200355 Phase 4
25 Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls Not yet recruiting NCT02809222 Phase 4
26 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4
27 King's Invasive Aspergillosis Study II Not yet recruiting NCT02875743 Phase 4
28 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
29 Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study Terminated NCT01326845 Phase 4
30 To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS. Terminated NCT01011283 Phase 4
31 Transfusion Effects in Myelodysplastic Patients: Limiting Exposure Withdrawn NCT00202371 Phase 4
32 The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome Unknown status NCT02042482 Phase 2, Phase 3
33 Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Unknown status NCT00234143 Phase 2, Phase 3
34 Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes Unknown status NCT01196715 Phase 3
35 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3
36 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3
37 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
38 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3
39 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3
40 Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS Unknown status NCT01417767 Phase 2, Phase 3
41 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3
42 Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) Image Unknown status NCT00172562 Phase 3
43 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
44 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
45 Bowel Preparation and Prokinetics in Capsule Endoscopy Unknown status NCT00275184 Phase 3
46 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3
47 The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol Approved for marketing NCT00438789 Phase 3
48 An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome Completed NCT01751867 Phase 3
49 Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome Completed NCT00004208 Phase 3
50 An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes Completed NCT01381809 Phase 3

Search NIH Clinical Center for Myelodysplastic Syndrome

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myelodysplastic Syndrome cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: myelodysplastic syndromes

Genetic Tests for Myelodysplastic Syndrome

Genetic tests related to Myelodysplastic Syndrome:

id Genetic test Affiliating Genes
1 Myelodysplastic Syndrome 29
2 Myelodysplastic Syndrome, Somatic 24 SF3B1 TET2 ASXL1

Anatomical Context for Myelodysplastic Syndrome

MalaCards organs/tissues related to Myelodysplastic Syndrome:

39
Myeloid, Bone, Bone Marrow, T Cells, Testes, Skin, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myelodysplastic Syndrome:
id Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Myelodysplastic Syndrome

Articles related to Myelodysplastic Syndrome:

(show top 50) (show all 2184)
id Title Authors Year
1
Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome. ( 28509586 )
2017
2
Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. ( 27687869 )
2017
3
Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome. ( 28487541 )
2017
4
Total coumarins of Hedyotis diffusa induces apoptosis of myelodysplastic syndrome SKM-1 cells by activation of caspases and inhibition of PI3K/Akt pathway proteins. ( 27988397 )
2017
5
Correction: Rapidly Progressing Myelodysplastic Syndrome Initially Presenting as Acute Leukemia. ( 28465876 )
2017
6
Relapsing Polychondritis with Myelodysplastic Syndrome: A Case Report. ( 28215949 )
2017
7
Rapidly progressive hemorrhagic pneumonia caused by Stenotrophomonas maltophilia occurring early after bone marrow transplantation in a patient with myelodysplastic syndrome. ( 28484160 )
2017
8
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). ( 28463633 )
2017
9
An Unlikely Rapid Transformation of Myelodysplastic Syndrome to Acute Leukemia: A Case Report. ( 28488979 )
2017
10
Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis. ( 27730343 )
2017
11
Myelodysplastic Syndrome Developing Presacral Extramedullary Hematopoiesis with Atypical MRI Findings. ( 28502939 )
2017
12
Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50A years of age: a systematic review and meta-analysis. ( 28470473 )
2017
13
Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. ( 28497239 )
2017
14
A randomized study comparing stem cell transplantation vs conventional therapy for low and intermediate risk myelodysplastic syndrome patients. ( 28494646 )
2017
15
WT1 Expression in Patients with Myelodysplastic Syndromes: A Variety of Possibilities in Future Clinical Practice. ( 27871071 )
2017
16
Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome. ( 27866185 )
2017
17
New polymorphisms of Xeroderma Pigmentosum DNA repair genes in myelodysplastic syndrome. ( 28472728 )
2017
18
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. ( 28514758 )
2017
19
Fatal Relapse of Myelodysplastic Syndrome in a Patient with HIV/Hepatitis C Coinfection Treated with Simeprevir/Sofosbuvir. ( 28088870 )
2017
20
Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports. ( 28527473 )
2017
21
A case of GATA2-related myelodysplastic syndrome with unbalanced translocation der(1;7)(q10;p10). ( 28066994 )
2017
22
Validation of the 2016 Revisions to the WHO Classification in Lower-Risk Myelodysplastic Syndrome. ( 28456995 )
2017
23
Reduced Intensity for Myelodysplastic Syndrome: Worth the Gamble? ( 28463632 )
2017
24
MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. ( 28084850 )
2017
25
CD34(+) megakaryocytes and megakaryocytic fragments in myelodysplastic syndrome. ( 28522465 )
2017
26
Successful haploidentical BMT with post-transplant cyclophosphamide for refractory autoimmune pancytopenia after cord blood transplant in pediatric myelodysplastic syndrome. ( 28067878 )
2017
27
Annotating Function to Differentially Expressed LincRNAs in Myelodysplastic Syndrome Using a Network-Based Method. ( 28472271 )
2017
28
Iron overload promotes erythroid apoptosis through regulating HIF-1a/ROS signaling pathway in patients with myelodysplastic syndrome. ( 28460338 )
2017
29
Generalised granuloma annulare associated with myelodysplastic syndrome. ( 27212203 )
2016
30
Comment: In response to "Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome. ( 27956372 )
2016
31
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT. ( 27650829 )
2016
32
Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes. ( 26508027 )
2016
33
High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. ( 26944860 )
2016
34
Increased expression of HERG K(+) channels contributes to myelodysplastic syndrome progression and displays correlation with prognosis stratification. ( 27077769 )
2016
35
Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome. ( 26812882 )
2016
36
Random-start controlled ovarian stimulation for emergency fertility preservation in a patient with myelodysplastic syndrome: a case report. ( 27191608 )
2016
37
MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study. ( 27987385 )
2016
38
Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5A %-a feasibility study. ( 27106699 )
2016
39
Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. ( 26851439 )
2016
40
Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome. ( 27077775 )
2016
41
A Case of Sweet's Syndrome Secondary to Myelodysplastic Syndrome - Diagnostic and Treatment Challenges. ( 28461837 )
2016
42
Use of darbepoetin alfa for myelodysplastic syndrome coincident with chronic kidney disease. ( 28509181 )
2016
43
Work up for the clopidogrel hypersensitivity that led to recognising the undiagnosed myelodysplastic syndrome. ( 27103925 )
2016
44
Myelodysplastic Syndrome Associated with Acquired Beta Thalassemia: "BTMDS". ( 27121565 )
2016
45
The Simultaneous Elevation of Oxidative Stress Markers and Wilms' Tumor 1 Gene during the Progression of Myelodysplastic Syndrome. ( 27980269 )
2016
46
Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. ( 26997444 )
2016
47
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. ( 26228814 )
2016
48
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). ( 27268068 )
2016
49
Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome and a brief review. ( 28054536 )
2016
50
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. ( 27650362 )
2016

Variations for Myelodysplastic Syndrome

UniProtKB/Swiss-Prot genetic disease variations for Myelodysplastic Syndrome:

66
id Symbol AA change Variation ID SNP ID
1 GATA2 p.Thr354Met VAR_066406 rs387906631
2 SETBP1 p.Asp868Asn VAR_063807 rs267607042
3 SETBP1 p.Gly870Ser VAR_063809 rs267607040
4 SETBP1 p.Ser869Asn VAR_069852
5 SETBP1 p.Thr873Arg VAR_069857

ClinVar genetic disease variations for Myelodysplastic Syndrome:

6 (show all 37)
id Gene Variation Type Significance SNP ID Assembly Location
1 MT-TL1 m.3242G> A single nucleotide variant Pathogenic rs193303018 GRCh37 Chromosome MT, 3242: 3242
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
3 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
4 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
5 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
6 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
7 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
8 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
9 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913502 GRCh37 Chromosome 15, 90631934: 90631934
10 GATA2 NM_001145661.1(GATA2): c.1061C> T (p.Thr354Met) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs387906631 GRCh37 Chromosome 3, 128200744: 128200744
11 GATA2 GATA2, 3-BP DEL, 1063ACA deletion risk factor
12 NRAS NM_002524.4(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
13 NRAS NM_002524.4(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
14 NRAS NM_002524.4(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
15 NRAS NM_002524.4(NRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
16 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
17 NRAS NM_002524.4(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
18 NRAS NM_002524.4(NRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh38 Chromosome 1, 114716126: 114716126
19 SF3B1 NM_012433.3(SF3B1): c.1998G> T (p.Lys666Asn) single nucleotide variant Pathogenic/Likely pathogenic rs377023736 GRCh37 Chromosome 2, 198267359: 198267359
20 TP53 NM_000546.5(TP53): c.743G> T (p.Arg248Leu) single nucleotide variant Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
21 TP53 NM_000546.5(TP53): c.743G> C (p.Arg248Pro) single nucleotide variant Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
22 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
23 DNMT3A NM_175629.2(DNMT3A): c.2645G> C (p.Arg882Pro) single nucleotide variant Pathogenic/Likely pathogenic rs147001633 GRCh37 Chromosome 2, 25457242: 25457242
24 DNMT3A NM_175629.2(DNMT3A): c.2645G> A (p.Arg882His) single nucleotide variant Pathogenic/Likely pathogenic rs147001633 GRCh37 Chromosome 2, 25457242: 25457242
25 DNMT3A NM_175629.2(DNMT3A): c.2644C> T (p.Arg882Cys) single nucleotide variant Pathogenic/Likely pathogenic rs377577594 GRCh37 Chromosome 2, 25457243: 25457243
26 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
27 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
28 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
29 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
30 IDH2 NM_001289910.1(IDH2): c.359G> A (p.Arg120Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913503 GRCh37 Chromosome 15, 90631838: 90631838
31 IDH2 NM_002168.3(IDH2): c.419G> T (p.Arg140Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913502 GRCh37 Chromosome 15, 90631934: 90631934
32 IDH2 NM_002168.3(IDH2): c.418C> T (p.Arg140Trp) single nucleotide variant Pathogenic/Likely pathogenic rs267606870 GRCh37 Chromosome 15, 90631935: 90631935
33 U2AF1 NM_001025203.1(U2AF1): c.470A> C (p.Gln157Pro) single nucleotide variant Likely pathogenic rs371246226 GRCh37 Chromosome 21, 44514777: 44514777
34 U2AF1 NM_006758.2(U2AF1): c.101C> T (p.Ser34Phe) single nucleotide variant Likely pathogenic rs371769427 GRCh37 Chromosome 21, 44524456: 44524456
35 U2AF1 NM_001025203.1(U2AF1): c.101C> A (p.Ser34Tyr) single nucleotide variant Likely pathogenic rs371769427 GRCh37 Chromosome 21, 44524456: 44524456
36 SF3B2 NM_006842.2(SF3B2): c.2099A> G (p.Glu700Gly) single nucleotide variant Likely pathogenic rs1057519960 GRCh37 Chromosome 11, 65830884: 65830884
37 TP53 NM_000546.5(TP53): c.742C> G (p.Arg248Gly) single nucleotide variant Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539

Copy number variations for Myelodysplastic Syndrome from CNVD:

7 (show top 50) (show all 82)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18423 1 14554092 29473750 Deletion Myelodysplastic syndrome
2 33240 1 43803475 43820135 Mutation MPL Myelodysplastic syndrome
3 40833 10 133929972 135293404 Duplication Myelodysplastic syndrome
4 44880 10 64500000 70600000 Loss Myelodysplastic syndrome
5 50727 11 119076986 119178859 Mutation CBL Myelodysplastic syndrome
6 51205 11 123900000 135006516 Gain Myelodysplastic syndrome
7 51499 11 127052052 133951370 Duplication Myelodysplastic syndrome
8 52451 11 1733191 2138300 Duplication Myelodysplastic syndrome
9 62482 12 10889756 25048970 Deletion Myelodysplastic syndrome
10 65983 12 239401 32382344 Deletion Myelodysplastic syndrome
11 72801 12 8689944 10025942 Deletion Myelodysplastic syndrome
12 97766 16 13109256 13949702 Deletion Myelodysplastic syndrome
13 108396 17 202809 18798804 Deletion Myelodysplastic syndrome
14 108397 17 202809 22129948 Deletion Myelodysplastic syndrome
15 109400 17 25800000 31800000 Gain Myelodysplastic syndrome
16 110294 17 31800000 38100000 Gain Myelodysplastic syndrome
17 116723 17 69689099 78513583 Duplication Myelodysplastic syndrome
18 116794 17 69987407 78623230 Deletion Myelodysplastic syndrome
19 118116 17 7571720 7590868 Mutation P53 Myelodysplastic syndrome
20 121808 18 47174275 49624685 Deletion Myelodysplastic syndrome
21 124116 19 1 59128983 Deletion Myelodysplastic syndrome
22 128856 19 43400000 45200000 Deletion Myelodysplastic syndrome
23 131185 19 53600000 59128983 Amplification Myelodysplastic syndrome
24 140406 2 197400000 204900000 Loss Myelodysplastic syndrome
25 152708 20 32473920 33605249 Deletion Myelodysplastic syndrome
26 153104 20 34400000 49800000 Deletion Myelodysplastic syndrome
27 153115 20 34507776 56709287 Deletion Myelodysplastic syndrome
28 153160 20 34853717 51702925 Deletion Myelodysplastic syndrome
29 158211 21 30500000 46944323 Microdeletion RUNX1 Myelodysplastic syndrome
30 160489 22 15438133 31661481 Triplication Myelodysplastic syndrome
31 168487 3 130292954 199251329 Duplication Myelodysplastic syndrome
32 180470 4 106067032 106200960 Mutation TET2 Myelodysplastic syndrome
33 181366 4 120601325 121421102 Deletion MAD2L1 Myelodysplastic syndrome
34 181367 4 120601325 121421102 Deletion PDE5A Myelodysplastic syndrome
35 181368 4 120601325 121421102 Deletion SAR1P3 Myelodysplastic syndrome
36 188218 4 60577199 61810493 Deletion Myelodysplastic syndrome
37 188320 4 62191591 126940390 Deletion Myelodysplastic syndrome
38 188506 4 65578799 66861924 Deletion EPHA5 Myelodysplastic syndrome
39 189909 4 80195990 82530576 Deletion ANTXR2 Myelodysplastic syndrome
40 189910 4 80195990 82530576 Deletion ARD1B Myelodysplastic syndrome
41 189911 4 80195990 82530576 Deletion BMP3 Myelodysplastic syndrome
42 189912 4 80195990 82530576 Deletion C4orf22 Myelodysplastic syndrome
43 189913 4 80195990 82530576 Deletion FGF5 Myelodysplastic syndrome
44 189914 4 80195990 82530576 Deletion GK2 Myelodysplastic syndrome
45 189915 4 80195990 82530576 Deletion PRDM8 Myelodysplastic syndrome
46 189916 4 80195990 82530576 Deletion PRKG2 Myelodysplastic syndrome
47 191854 5 102760027 157708888 Deletion Myelodysplastic syndrome
48 193154 5 125503105 161513040 Deletion Myelodysplastic syndrome
49 200025 5 48400000 180915260 Deletion GLRA1 Myelodysplastic syndrome
50 200026 5 48400000 180915260 Deletion SH3TC2 Myelodysplastic syndrome

Expression for Myelodysplastic Syndrome

Search GEO for disease gene expression data for Myelodysplastic Syndrome.

Pathways for Myelodysplastic Syndrome

GO Terms for Myelodysplastic Syndrome

Biological processes related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.95 ASXL1 GATA2 IRF1 NPM1 RUNX1 TET2
2 transcription from RNA polymerase II promoter GO:0006366 9.88 GATA2 IRF1 NPM1 RUNX1 WT1
3 positive regulation of cell proliferation GO:0008284 9.85 CSF2 EPO FLT3 IL3 NPM1
4 positive regulation of transcription, DNA-templated GO:0045893 9.85 EPO IRF1 NPM1 PRDM16 RUNX1 WT1
5 positive regulation of DNA replication GO:0045740 9.5 CSF2 EPO IL3
6 embryonic placenta development GO:0001892 9.49 CSF2 GATA2
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.46 CSF2 EPO FLT3 IL3
8 dendritic cell differentiation GO:0097028 9.43 CSF2 FLT3
9 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.43 CSF2 EPO IL3
10 myeloid progenitor cell differentiation GO:0002318 9.13 FLT3 MLF1 TET2
11 hemopoiesis GO:0030097 9.02 ASXL1 FLT3 GATA2 RUNX1 TET2

Molecular functions related to Myelodysplastic Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.28 ASXL1 GATA2 IRF1 MLF1 PRDM16 RUNX1
2 C2H2 zinc finger domain binding GO:0070742 9.16 GATA2 WT1
3 regulatory region DNA binding GO:0000975 8.96 IRF1 RUNX1

Sources for Myelodysplastic Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....